Ledifos is a fixed-dose combination medication containing ledipasvir and sofosbuvir, used for the treatment of chronic hepatitis C virus (HCV) infection. It offers a highly effective, oral treatment that has revolutionised HCV care by improving cure rates, reducing treatment duration, and eliminating the need for injectable interferon-based therapies. Ledifos is often prescribed as part of a complete antiviral treatment plan and is particularly valued for its once-daily dosing convenience.

Mechanism of Action
Ledifos works by directly targeting the replication cycle of the hepatitis C virus through two distinct mechanisms:

• Sofosbuvir is a nucleotide analog inhibitor of the NS5B polymerase, an enzyme critical for viral RNA replication. Once inside the body, it is converted to its active form, which incorporates into the viral RNA chain and causes premature chain termination, effectively halting the virus’s ability to reproduce.

• Ledipasvir is an inhibitor of the HCV NS5A protein, which plays a key role in both viral replication and assembly. By blocking this protein, ledipasvir further disrupts the replication process.

  Uses
  Ledifos is mainly used for:

  • Treatment of chronic hepatitis C infection, particularly genotypes 1, 4, 5, and 6

  • Suitable for both treatment-naive patients and those who have not responded to previous therapies

  • Used in combination with other medications or as monotherapy, depending on the individual patient profile and presence of liver damage such as cirrhosis

    Adverse Effects

    Common side effects may include:

    • Headache

    • Fatigue

    • Nausea

    • Insomnia

    • Diarrhoea